Lev Dorfman1,2, Jacob Amir1,2, Joseph Attias3,4, Efraim Bilavsky5,6. 1. Department of Pediatrics C, Schneider Children's Medical Center, Petah Tiqva, Israel. 2. Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel. 3. Institute of Audiology and Clinical Neurophysiology, Schneider Children's Medical Center, Petah Tiqva, Israel. 4. Department of Communication Sciences & Disorders, University of Haifa, Haifa, Israel. 5. Department of Pediatrics C, Schneider Children's Medical Center, Petah Tiqva, Israel. yoji@netvision.net.il. 6. Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel. yoji@netvision.net.il.
Abstract
Recently, valganciclovir treatment of symptomatic congenital cytomegalovirus (cCMV) disease, commenced during the neonatal period (≤ 4 weeks), was found to improve hearing and developmental outcome. However, many children (symptomatic or asymptomatic at birth) present only after 4 weeks of age. The purpose of this observational retrospective study was to describe the outcome and safety of valganciclovir therapy in infants with cCMV who started treatment > 4 weeks of life. Of the 91children who started antiviral treatment > 4 weeks of age, 66/298 (22.2%) were symptomatic at birth; 25/217 (11.5%) were asymptomatic at birth. Treatment was initiated on average at 14 weeks of age (range 5-77 weeks) and at 53.3 weeks (range 12-156 weeks), respectively. Of the 45 affected ears in the symptomatic group, 30 (66.7%) improved and only 2 (4.4%) deteriorated, with most of the improved ears (27/30, 90%) returning to normal. In the asymptomatic group, late-onset treatment was initiated and out of the 42 deteriorated ears, 38 (90.5%) improved after at least 1 year of follow-up. Hematological adverse events, i.e., neutropenia, were noted in a minority of cases (4.4%). Conclusion: Our study demonstrates the benefits and safety aspects of treating symptomatic and asymptomatic children with cCMV even beyond the recommended neonatal period.What is Known:• Valganciclovir treatment of symptomatic congenital cytomegalovirus (cCMV) disease, commenced during the neonatal period, is beneficial in improving hearing and developmental outcome.• However, data of treatment started beyond the neonatal period is lacking.What is New:• Our study demonstrates the benefits of treating symptomatic children with cCMV as well as asymptomatic children that develop late-onset hearing loss even beyond the recommended neonatal period.• This was true for symptomatic children who presented > 4 weeks as well as to those were asymptomatic at birth but experienced late hearing deterioration.
Recently, valganciclovir treatment of symptomatic congenital cytomegalovirus (cCMV) disease, commenced during the neonatal period (≤ 4 weeks), was found to improve hearing and developmental outcome. However, many children (symptomatic or asymptomatic at birth) present only after 4 weeks of age. The purpose of this observational retrospective study was to describe the outcome and safety of valganciclovir therapy in infants with cCMV who started treatment > 4 weeks of life. Of the 91children who started antiviral treatment > 4 weeks of age, 66/298 (22.2%) were symptomatic at birth; 25/217 (11.5%) were asymptomatic at birth. Treatment was initiated on average at 14 weeks of age (range 5-77 weeks) and at 53.3 weeks (range 12-156 weeks), respectively. Of the 45 affected ears in the symptomatic group, 30 (66.7%) improved and only 2 (4.4%) deteriorated, with most of the improved ears (27/30, 90%) returning to normal. In the asymptomatic group, late-onset treatment was initiated and out of the 42 deteriorated ears, 38 (90.5%) improved after at least 1 year of follow-up. Hematological adverse events, i.e., neutropenia, were noted in a minority of cases (4.4%). Conclusion: Our study demonstrates the benefits and safety aspects of treating symptomatic and asymptomatic children with cCMV even beyond the recommended neonatal period.What is Known:• Valganciclovir treatment of symptomatic congenital cytomegalovirus (cCMV) disease, commenced during the neonatal period, is beneficial in improving hearing and developmental outcome.• However, data of treatment started beyond the neonatal period is lacking.What is New:• Our study demonstrates the benefits of treating symptomatic children with cCMV as well as asymptomatic children that develop late-onset hearing loss even beyond the recommended neonatal period.• This was true for symptomatic children who presented > 4 weeks as well as to those were asymptomatic at birth but experienced late hearing deterioration.
Entities:
Keywords:
Congenital cytomegalovirus; Congenital infection; Cytomegalovirus; Ganciclovir; Hearing loss; Late hearing loss; Late treatment; Valganciclovir; cCMV
Authors: Suzanne E Luck; Jantien W Wieringa; Daniel Blázquez-Gamero; Philipp Henneke; Katharina Schuster; Karina Butler; Maria Grazia Capretti; Maria José Cilleruelo; Nigel Curtis; Francesca Garofoli; Paul Heath; Elias Iosifidis; Nigel Klein; Giuseppina Lombardi; Hermione Lyall; Tea Nieminen; Dasja Pajkrt; Vassiliki Papaevangelou; Klara Posfay-Barbe; Laura Puhakka; Emmanuel Roilides; Pablo Rojo; Jesús Saavedra-Lozano; Teshri Shah; Mike Sharland; Harri Saxen; Ann C T M Vossen Journal: Pediatr Infect Dis J Date: 2017-12 Impact factor: 2.129
Authors: William D Rawlinson; Suresh B Boppana; Karen B Fowler; David W Kimberlin; Tiziana Lazzarotto; Sophie Alain; Kate Daly; Sara Doutré; Laura Gibson; Michelle L Giles; Janelle Greenlee; Stuart T Hamilton; Gail J Harrison; Lisa Hui; Cheryl A Jones; Pamela Palasanthiran; Mark R Schleiss; Antonia W Shand; Wendy J van Zuylen Journal: Lancet Infect Dis Date: 2017-03-11 Impact factor: 25.071
Authors: Julie Goderis; Annelies Keymeulen; Koenraad Smets; Helen Van Hoecke; Els De Leenheer; An Boudewyns; Christian Desloovere; Rudolf Kuhweide; Marie Muylle; Liesbeth Royackers; Isabelle Schatteman; Ingeborg Dhooge Journal: J Pediatr Date: 2016-02-05 Impact factor: 4.406
Authors: David W Kimberlin; Penelope M Jester; Pablo J Sánchez; Amina Ahmed; Ravit Arav-Boger; Marian G Michaels; Negar Ashouri; Janet A Englund; Benjamin Estrada; Richard F Jacobs; José R Romero; Sunil K Sood; M Suzanne Whitworth; Mark J Abzug; Mary T Caserta; Sandra Fowler; Jorge Lujan-Zilbermann; Gregory A Storch; Roberta L DeBiasi; Jin-Young Han; April Palmer; Leonard B Weiner; Joseph A Bocchini; Penelope H Dennehy; Adam Finn; Paul D Griffiths; Suzanne Luck; Kathleen Gutierrez; Natasha Halasa; James Homans; Andi L Shane; Michael Sharland; Kari Simonsen; John A Vanchiere; Charles R Woods; Diane L Sabo; Inmaculada Aban; Huichien Kuo; Scott H James; Mark N Prichard; Jill Griffin; Dusty Giles; Edward P Acosta; Richard J Whitley Journal: N Engl J Med Date: 2015-03-05 Impact factor: 91.245
Authors: David W Kimberlin; Chin-Yu Lin; Pablo J Sánchez; Gail J Demmler; Wayne Dankner; Mark Shelton; Richard F Jacobs; Wendy Vaudry; Robert F Pass; Jan M Kiell; Seng-jaw Soong; Richard J Whitley Journal: J Pediatr Date: 2003-07 Impact factor: 4.406